Europe gives generics merger the green flag


 

Two of the top five global generic medicines manufactures, Watson and Actavis, have been given the go-ahead to merge by the European Commission. Under the deal, Watson – which is predominantly active in the US – will acquire Actavis for €4.25 billion (£3.4 billion).

The combined company will become the third largest generics business in the world, after Israel’s Teva, and Sandoz, the generics arm of Swiss firm Novartis. According to Watson’s chief executive, Paul Bisaro, the aim of the acquisition is to strengthen the company’s position outside of the US. ‘In a single, commercially compelling transaction, we more than double Watson's international access and strengthen our commercial position in key established European markets as well as exciting emerging growth markets, including Central and Eastern Europe and Russia,’ he says.


Related Content

Allergan steps away from generics with sale to Teva

29 July 2015 Business

news image

$40.5 billion deal gives Allergan cash to clear debt and fund further acquisitions, and catapults Teva into global pharma top...

Megamerger brings Actavis into R&D race

25 February 2014 Business

news image

$25bn Forest Labs takeover will see generics giant take on patented products

Most Read

Super-elastic wire stretches without losing power

23 July 2015 Research

news image

Fibre that can stretch 14 times its own length could find its way into robotic arms and satellites

Weaving is believing

23 July 2015 The Crucible

news image

Philip Ball unpicks the history of science’s woollen wardrobe

Most Commented

Scientist imprisoned over fraudulent HIV vaccine research

6 July 2015 News and Analysis

news image

Former Iowa State University researcher gets four-and-a-half years in prison for faking vaccine research funded by the NIH

Single polymer pill could deliver entire drug course in one go

27 July 2015 Research

news image

Flexible elastomer ring springs open to stay in stomach and could slowly release drugs over days